Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sudheer Surpure

Oral & Maxillofacial Surgery Flagstaff, AZ Medical Doctor

NPI 1235216185 CMS profile 654765

1600 W University Ave Ste 101, Flagstaff, AZ 86001

Open in the dashboard

General payments

$31,462

88 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sudheer Surpure of Flagstaff, AZ is reported in the CMS Open Payments database as having received $31,462 across 88 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Oral & Maxillofacial Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $36 1
2024 General $12,322 20
2023 General $7,856 14
2022 General $171 5
2021 General $235 5
2020 General $677 15
2019 General $10,165 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sudheer Surpure
  • Oral & Maxillofacial Surgery median
  • Middle half of Oral & Maxillofacial Surgery
  • National median

In program year 2025, general payments to Sudheer Surpure were reported at $36. Among 792 Oral & Maxillofacial Surgery profiles paid that year, the median was $184 and the middle half received between $61 and $541.

Show as a table
Year Sudheer Surpure Oral & Maxillofacial Surgery median Middle half National median
2019 $10,165 $178 $56–$584 $163
2020 $677 $106 $38–$316 $114
2021 $235 $165 $57–$511 $132
2022 $171 $173 $63–$494 $149
2023 $7,856 $184 $62–$521 $160
2024 $12,322 $197 $65–$603 $164
2025 $36 $184 $61–$541 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Acumed LLC $20,197 34 payments
  2. Osteomed LLC $10,407 30 payments
  3. Smith+Nephew, Inc. $195 10 payments
  4. KLS-Martin L.P. $175 5 payments
  5. AxoGen $152 2 payments
  6. Stryker Corporation $137 1 payment
  7. DePuy Synthes Sales Inc. $72 2 payments
  8. Zimmer Biomet Holdings, Inc. $43 1 payment
  9. Geistlich Pharma, North America, Inc. $35 1 payment
  10. Integra LifeSciences Corporation $34 1 payment
  11. Other $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,768 8 payments
  2. Consulting Fee $4,430 2 payments
  3. Travel and Lodging $4,054 21 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,900 1 payment
  5. Food and Beverage $1,980 49 payments
  6. Education $330 7 payments
Products named General payments · program years 2019–2025
  1. OsteoMed Craniomaxillofacial $17,924 29 payments
  2. OsteoMed Craniomaxillofacial $14,553 23 payments
  3. CMF-Other $9,381 11 payments
  4. OsteoMed Craniomaxillofacial $2,300 2 payments
  5. AccuPlate Patient-Specific Plate $1,665 2 payments
  6. OsteoMed Craniomaxillofacial $1,600 1 payment
  7. OsteoMed Craniomaxillofacial $1,041 6 payments
  8. xPower-Osteopower $604 2 payments
  9. CMF-OSA $418 6 payments
  10. CMF-Medical Model $177 4 payments
  11. Other $1,671 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

330

Median for Maxillofacial Surgery: 343

Drug cost

$1,296

Median for Maxillofacial Surgery: $1,437

Branded share of claims

34.8%

Median for Maxillofacial Surgery: 21.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Chlorhexidine Gluconate Generic 107 $412
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 83 $333
Amoxicillin Generic 92 $238
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 19 $126
Clindamycin Hcl Generic 16 $124
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 13 $63

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 692 Part D prescribers listed as Maxillofacial Surgery; they describe a distribution and say nothing about conduct.

Records

88 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Oral & Maxillofacial Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record